Herbert Schuster

Herbert Schuster

UNVERIFIED PROFILE

Are you Herbert Schuster?   Register this Author

Register author
Herbert Schuster

Herbert Schuster

Publications by authors named "Herbert Schuster"

Are you Herbert Schuster?   Register this Author

24Publications

331Reads

17Profile Views

[From phenotype to genotype: a glimpse behind the scenes of an unending story].

Dtsch Med Wochenschr 2015 Dec 16;140(25):1920-3. Epub 2015 Dec 16.

Institut Experimental and Clinical Research Center (ECRC), eine gemeinsame Einrichtung des Max-Delbrück-Centrums für Molekulare Medizin (MDC) und der Charité Medizinischen Fakultät, Berlin.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0041-107586DOI Listing
December 2015

Avoidance of the Ames test liability for aryl-amines via computation.

Bioorg Med Chem 2011 May 3;19(10):3173-82. Epub 2011 Apr 3.

Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmc.2011.03.066DOI Listing
May 2011

Relating two deep-rooted pedigrees from Central Germany by high-resolution Y-STR haplotyping.

Forensic Sci Int Genet 2007 Jun 13;1(2):125-8. Epub 2007 Mar 13.

Department of Forensic Molecular Biology, Erasmus MC-University Medical Center Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.fsigen.2007.02.004DOI Listing
June 2007

The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk.

Authors:
Herbert Schuster

Expert Rev Cardiovasc Ther 2007 Mar;5(2):177-93

INFOGEN, Xantener Strasse 10, 10707 Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14779072.5.2.177DOI Listing
March 2007

Rosuvastatin may be more effective than atorvastatin in African-Americans with hypercholesterolemia.

Evid Based Cardiovasc Med 2006 Jun 24;10(2):96-100. Epub 2006 May 24.

Atherosclerosis and Vascular Biology Laboratory, Federal University of Sao Paulo, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebcm.2006.04.017DOI Listing
June 2006

Does rosuvastatin improve lipid levels in patients with the metabolic syndrome more effectively than atorvastatin?

Authors:
Herbert Schuster

Nat Clin Pract Cardiovasc Med 2006 Feb;3(2):74-5

Charité Humboldt University of Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncpcardio0460DOI Listing
February 2006

Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.

Int J Cardiol 2005 Apr;100(2):309-16

Southwestern Ontario Medical Education Network Windsor, Schulich School of Medicine, University of Western Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijcard.2004.12.011DOI Listing
April 2005

Investigating cardiovascular risk reduction--the Rosuvastatin GALAXY Programme.

Expert Opin Pharmacother 2004 May;5(5):1187-200

Humboldt University, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.5.5.1187DOI Listing
May 2004

Case reports illustrate consequences of ATP III in practice.

Authors:
Herbert Schuster

Am J Manag Care 2003 Aug;Suppl:5-6

Humboldt University, Berlin.

View Article

Download full-text PDF

Source
August 2003

Single nucleotide polymorphism haplotypes in the cholesteryl-ester transfer protein (CETP) gene and lipid phenotypes.

Hum Hered 2002 ;54(4):166-73

Max Delbrück Center, Medical Faculty of the Charité, Humboldt University of Berlin, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000070662DOI Listing
July 2003

DNA testing for familial hypercholesterolemia: improving disease recognition and patient care.

Am J Pharmacogenomics 2002 ;2(4):253-62

Max Delbruck Center for Molecular Medicine, University Hospital Charité, Humboldt University of Berlin, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2165/00129785-200202040-00005DOI Listing
May 2003

Managing the high-risk patient: therapeutic approaches in 2002.

Atheroscler Suppl 2003 Mar;4(1):15-20

Humboldt University Berlin, Droysenstr. 1, 10629 Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s1567-5688(03)00005-9DOI Listing
March 2003

The impact of fatty acid oxidation on energy utilization: targets and therapy.

Curr Pharm Des 2002 ;8(14):1199-227

Novartis Pharmaceuticals Corporation, Novartis Institute for Biomedical Research, Metabolic and Cardiovascular Diseases Department, Summit, NJ 07901, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1381612023394692DOI Listing
October 2002

High risk/high priority: familial hypercholesterolemia--a paradigm for molecular medicine.

Authors:
Herbert Schuster

Atheroscler Suppl 2002 Apr;2(4):27-30; discussion 30-2

Infogen GmbH and Max Delbruck Center, Humboldt University, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s1567-5688(01)00019-8DOI Listing
April 2002